ClinicalTrials.gg
CompletedNCT01822249Updated Jul 26, 2018

Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

A Phase 2 interventional study of EPI-743 and Placebo in Rett Syndrome, sponsored by Edison Pharmaceuticals Inc. Completed at 1 site in Italy. Open to female participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2018-07-26.

Sponsored by Edison Pharmaceuticals Inc (part of PTC Therapeutics) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
Up to 18 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Rett Syndrome with a site in Italy — 3 open to participants now, 3 under way, 1 of them phase 3. Rett Syndrome · Italy.

Started
2013
the only one that year
Phase 2
Only one
of the 11
Registered
1st of 11
by date
Lead sponsor
1 of 11
Edison Pharmaceuticals Inc

Among the 11 studies in Rett Syndrome with a site in Italy, this one is the only one that started in 2013, is the only one in phase 2, and was the 1st registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

3 of the 11 studies in Rett Syndrome with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: Up to 18 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Rett Syndrome with a site in Italy, or all of them as a file.
02

Study summary

Rett syndrome is a severe neurodevelopmental disorder that primarily affects female children. Rett syndrome is characterized by significant elevation in blood markers of oxidative stress. EPI-743 is a novel therapeutic with demonstrated efficacy and safety in the treatment of disorders characterized by oxidative stress. The purpose of this study is to examine the safety and efficacy of EPI-743 in a population of children with Rett syndrome.

03

Conditions studied

  • Rett Syndrome

Browse trials for

Keywords

  • Rett syndrome
  • EPI-743
  • Edison
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Rett syndrome with disease stage 1-2
  • Abnormality of at least two disease biomarker levels
  • Confirmed MeCP2 mutation
  • Patient or patient's guardian able to consent and comply with protocol requirements
  • Abstention from use of Coenzyme Q10, vitamin E and Idebenone two weeks prior to enrollment into the study

Exclusion criteria

Exclusion Criteria:

  • Any condition, which in the opinion of the investigator could compromise the subject's safety or adherence to treatment with EPI-743.
  • allergy or to EPI-743 or to any of the of with EPI-743 (eg., sesame oil).
  • Clinically significant allergy or hypersensitivity to Vitamin E
  • Lack of confirmation of MeCP2 mutation
  • Clinical history of bleeding or abnormal baseline PT/
  • Diagnosis of any other concurrent inborn error of metabolism
  • Hepatic insufficiency with LFTs greater than 3 times
  • Renal insufficiency requiring dialysis
  • End stage cardiac failure
  • Fat malabsorption syndromes precluding drug absorption
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    EPI-743 15 mg/kg

    Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily

    Drug: EPI-743

  • Placebo comparator
    Placebo

    Subjects in this arm will receive placebo at a volume equivalent to the volume of EPI-743 they would receive if in active group based on their weight

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Rett Syndrome Clinical Severity Sore

    Measure of disease progression

    Time frame: Change at six months from baseline

Secondary outcomes

  1. Oxidative Stress Biomarkers

    Time frame: Change at six months from baseline

  2. Head circumference

    Time frame: Change at six months from baseline

  3. Rett syndrome behavioral questionnaire

    Time frame: Change at six months from baseline

  4. PedsQL

    Time frame: Change at six months from baseline

  5. Number of Drug-related adverse and serious adverse events

    Time frame: Six months

  6. Respiratory Disturbance Index (RDI)

    RDI will be determined on polysomnography study

    Time frame: Change at six months from baseline

07

Study locations

1 site
  • University of Siena
    Siena, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Dec 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2013
First posted
Apr 2, 2013
Start
Jan 2013
Primary completionActual
Dec 2013
CompletionActual
Jan 2014
Last update
Jul 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01822249
Responsible party
Sponsor
First posted
Apr 2, 2013
Start date
Jan 2013
Primary completion
Dec 2013
Completion
Jan 2014
Last update
Jul 26, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion